Piekos Brian
Chief Financial Officer
Piekos Brian has filed 5 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Jun 11, 2026.
On the most recent filing, Piekos Brian is listed as Chief Financial Officer at KalVista Pharmaceuticals, Inc. Inside the rolling window, Piekos Brian reported no open-market purchases and 4 open-market sales totaling $165K in KALV. The largest disclosed transaction in the window is a sale of 4,471 KALV shares on Nov 24, 2025, worth $60K.
Companies traded
Other insiders at KALV
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$165K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Piekos Brian made?
Piekos Brian has filed 5 SEC Form 4 filings (9 transaction rows) across 1 company since 2025.
Which companies does Piekos Brian trade?
Piekos Brian has filed SEC Form 4 disclosures for 1 company, including KALV.
When was Piekos Brian's most recent SEC Form 4 filing?
Piekos Brian's most recent SEC Form 4 filing on Tracefour is dated Jun 11, 2026.
What is Piekos Brian's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Piekos Brian is listed as Chief Financial Officer.
What is Piekos Brian's total buy and sell value in the current window?
Inside the rolling retention window, Piekos Brian bought $0 and sold $165K based on SEC Form 4 filings.
What was Piekos Brian's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,471 KALV shares on 2025-11-24, worth $60K, per SEC Form 4 filings.